{
    "nctId": "NCT05501158",
    "briefTitle": "CYP2D6 Genotypes and Breast Cancer Clinical Outcomes in the Indonesian Population",
    "officialTitle": "CYP2D6 Genotypes and Breast Cancer Clinical Outcomes in the Indonesian Population (Pengaruh Genotipe CYP2D6 Terhadap Efektivitas Penggunaan Tamoksifen Untuk Pasien Kanker Payudara ER+ Pada Populasi Indonesia)",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 150,
    "primaryOutcomeMeasure": "Overall Survival rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. female\n2. diagnosed with ER+ breast cancer\n3. have been genotyped and classified as PM and IM in the previous study\n4. are recommended by doctor to take tamoxifen 40 mg according to their metabolizer profile\n5. have finished the definitive therapy course (surgery, chemotherapy, or radiotherapy).\n\nExclusion Criteria:\n\n1. have other primary cancer aside from breast cancer.\n2. those with residual tumor cells/have experienced second primary breast tumor.\n3. patients who are recommended by doctor to switch to aromatase inhibitors (AI)",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}